Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
British scientists will start testing Merck & Co Inc (NYSE:MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, reported Reuters.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- The pill is approved in Britain for use in people with mild to moderate COVID-19. Still, it is unknown whether it would work in patients hospitalized with severe illness, researchers of the RECOVERY trial said.
- The study will compare 800 mg doses of molnupiravir, given twice daily for five days, with standard care for adult patients in hospitals because of COVID-19.
- Related: Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters.
- "Adding molnupiravir (to the study) will allow us to study this drug on its own, but also in combination with other COVID-19 treatments," said Peter Horby, joint chief investigator of the trial and Oxford University professor.
- Related: UK Calls For Additional Doses Of COVID-19 Antivirals From Merck, Pfizer.
- Price Action: MRK shares are down 3.14% at $77.47 during the market session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.